Literature DB >> 2862109

Seroepidemiologic studies of human T-cell leukemia/lymphoma virus type I in Jamaica.

J Clark, C Saxinger, W N Gibbs, W Lofters, L Lagranade, K Deceulaer, A Ensroth, M Robert-Guroff, R C Gallo, W A Blattner.   

Abstract

The prevalence of HTLV-I antibodies was evaluated in Jamaica among persons with various malignant, infectious, autoimmune and hematologic disorders and in clinically normal persons. Results document that: (1) the prevalence of HTLV-I antibodies in this population increases with age; (2) overall, there is no significant difference in the antibody prevalence between males and females; (3) antibody-positive individuals are born in all major regions of the island and geographical variance in antibody prevalence by place of birth was not prominent; (4) there is further confirmation of the high prevalence of HTLV-I antibody-positive lymphomas in Jamaica; and (5) the prevalence of HTLV-I antibodies in hemophiliacs, patients with chronic lymphocytic leukemia (CLL), myelogenous leukemias, and patients with breast cancer is higher than in the age-matched population without malignancies, although none of these differences were statistically significant. The increased prevalence in hemophiliacs is most likely related to their frequent transfusion with blood products, but it has not yet been determined whether the prevalence in patients with other diseases is related to their diseases or other as yet undefined factors in common.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2862109     DOI: 10.1002/ijc.2910360107

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  Prevalence of human T-lymphotropic virus in civilian applicants for the United States Armed Forces.

Authors:  C R Roberts; D R Fipps; J F Brundage; S E Wright; M Goldenbaum; S S Alexander; D S Burke
Journal:  Am J Public Health       Date:  1992-01       Impact factor: 9.308

Review 2.  The epidemiology of HTLV-I infection.

Authors:  N Mueller
Journal:  Cancer Causes Control       Date:  1991-01       Impact factor: 2.506

3.  Infection with human T cell leukaemia/lymphoma virus type I in patients attending an antenatal clinic in London.

Authors:  J H Tosswill; A E Ades; C Peckham; P P Mortimer; J N Weber
Journal:  BMJ       Date:  1990-07-14

4.  High endemicity of human T-cell lymphotropic virus type 1 among pregnant women in peru.

Authors:  Jorge O Alarcón; Heidi B Friedman; Silvia M Montano; Joseph R Zunt; King K Holmes; Gerald V Quinnan
Journal:  J Acquir Immune Defic Syndr       Date:  2006-08-15       Impact factor: 3.731

5.  Expression of glucose transporter 1 confers susceptibility to human T-cell leukemia virus envelope-mediated fusion.

Authors:  Ayse Kubra Coskun; Richard E Sutton
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  A seroepidemiologic survey of human T-cell lymphotropic virus type I in two Hawaiian hematologic-oncologic practices.

Authors:  J T Kimata; S A Kaneshiro; D W Kwock; S Nakamura; M M Kaneshiro; J M Nakamura
Journal:  West J Med       Date:  1989-03

7.  Modes of transmission and evidence for viral latency from studies of human T-cell lymphotrophic virus type I in Japanese migrant populations in Hawaii.

Authors:  W A Blattner; A Nomura; J W Clark; G Y Ho; Y Nakao; R Gallo; M Robert-Guroff
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

8.  Prevalence of antibody to human T-cell lymphotropic virus type I/II in people of Caribbean origin in Toronto.

Authors:  J Chiavetta; J Nusbacher; F Tam; A Wall; J Steaffens; H Lee
Journal:  CMAJ       Date:  1992-11-15       Impact factor: 8.262

9.  Imaging of human T-lymphotropic virus type I-associated chronic progressive myeloneuropathies.

Authors:  F Alcindor; R Valderrama; M Canavaggio; H Lee; A Katz; C Montesinos; R E Madrid; R R Merino; P A Pipia
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

10.  Human T lymphotropic virus type 1 in a seronegative B chronic lymphocytic leukemia patient.

Authors:  Pinhas Stark; Walter Bodemer; Horst Hannig; Jacob Luboshitz; Matityahu Shaklai; Batya Shohat
Journal:  Med Microbiol Immunol       Date:  2003-01-09       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.